Help shape our input into Scotland's assessment of alpelisib (Piqray) with fulvestrant

[Sukhi_BCN]

Hi Liz, 

Thank you so much for your message. 

If you do start this treatment, it wouldn't be too late share your views, as there are several stages of the drug assessment process so we may be able to reflect on any views you share, later in the process. It would be so helpful to hear your experience, to make sure the voices of people affected by breast cancer are heard, so If you do start on this treatment, please feel free to email me at Policy@breastcancernow.org.

Thanks again, 

Sukhi 

[Liz0418]

Hi I am awaiting blood results to show if I will be suitable for this will know end of August apparently results take 2 months . Would it be too late for me to be of help. Liz

[Sukhi_BCN]

Hi all,

My name is Sukhi, and I work in Breast Cancer Now’s Policy team.

I’m looking to hear from people with experience of the drug treatment alpelisib (also known as Piqray) when used in combination with fulvestrant for the treatment of certain patients with hormone-receptor positive, PIK3CA-mutated locally advanced or secondary breast cancer.

The treatment was recently approved for use on the NHS in England, and now the Scottish Medicines Consortium (SMC) is assessing whether it can be made available on the NHS in Scotland. We‘ll be involved at every step to ensure eligible patients will be able to access this treatment and the first stage is submitting written evidence to the SMC.

If you have experience of the treatment and want to help shape Breast Cancer Now's input, please contact me at policy@breastcancernow.org by 29 August 2022. You can choose how to share your experience and views, for example, you could answer a couple of questions over email, or we can arrange a short call at a time that suits you.

Many thanks,

Sukhi